A significant amount of money ($1.76B annually in the United States) is spent on workforce development programs, while there is limited research on the effectiveness of workforce development programs in meeting their program objectives and assisting program participants in attaining employment. This study evaluated the New Choices Program, a workforce development program offered by PA Women Work, to help its clients obtain employment and overcome personal and professional barriers. The program has historically been offered in a 30-hour in person format but was forced to be modified to a 10-hour virtual program when the COVID-19 pandemic restrictions began. This program evaluation included a comparative analysis of the perceptions of participants in the 30-hour in person program and the 10-hour virtual program. It was found that participants in both the 30-hour in person program and 10-hour virtual program perceived the program positively, experienced an increase in self-confidence and belonging, which led to either obtaining employment or being better prepared for the job search process. The data will help inform the New Choices program stakeholders on programmatic improvements and how best to structure the program in the post-pandemic employment world.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.evalprogplan.2024.102507 | DOI Listing |
Obes Res Clin Pract
January 2025
Department of Pediatrics, National Taiwan University Hospital, National Taiwan University Children's Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, National Taiwan University Children's Hospital, Taipei, Taiwan; Department and Graduate Institute of Medical Education and Bioethics, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:
Background: Lifestyle modification (LM) is the mainstay in the management of obese children. This study aimed to investigate the long-term effects of a pediatric cohort participating in a hospital-based LM program.
Methods: Overweight/obese children and adolescents who visited a multidisciplinary LM program "The Health and Vitality Clinic" were included.
An Bras Dermatol
January 2025
Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil.
J Formos Med Assoc
January 2025
Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng-Kung University, Tainan, Taiwan; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Quality of life (QOL) is important for evaluating medical care outcomes. In chronic kidney disease (CKD) population, generic instruments, such as WHOQOL-BREF and EQ-5D, are commonly used for comparing various medical conditions for policy-making purposes. However, their psychometric properties have not yet been validated in non-dialysis CKD population.
View Article and Find Full Text PDFJ Formos Med Assoc
January 2025
Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Controlling hypertension has become an important issue in the elderly population in whom neurological comorbidities are highly prevalent. Most of the large-scale trials focusing on hypertension management in older populations have excluded patients with comorbid neurological disorders. However, this population requires special considerations, as the benefits of antihypertensive agents are mostly uncertain and there is a higher risk of adverse events.
View Article and Find Full Text PDFUrol Oncol
January 2025
Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele University, Milan, Italy.
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review we examine the clinical development program of TAR-200, a novel targeted releasing system designed to provide sustained intravesical delivery of gemcitabine to address the needs of patients with NMIBC and of those with MIBC. We describe the concept and design of TAR-200 and the clinical development of this gemcitabine intravesical system in the SunRISe portfolio of studies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!